2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-139607
    SSAO inhibitor-1 2242883-04-9 98%
    SSAO inhibitor-1 is a semicarbazide-sensitive amine oxidase (SSAO) inhibitor. SSAO inhibitor-1 has anti-inflammatory activity and can be used for liver diseases research.
    SSAO inhibitor-1
  • HY-141454
    TLR8 agonist 2 2412937-64-3 98%
    TLR8 agonist 2 is a potent and selective TLR8 agonist with an EC50 of 3 nM for human TLR8. TLR8 agonist 2 shows less active against human TLR7 (EC50 of 33.33 μM).
    TLR8 agonist 2
  • HY-142119
    Penehyclidine 87827-02-9 98%
    Penehyclidine, a anticholinergic agent, is a selective antagonist of M1 and M3 receptors. Penehyclidine activates NF-kβ in lung tissue and inhibits the release of inflammatory factors. Penehyclidine can alleviate the pulmonary inflammatory response in rats with chronic obstructive pulmonary disease (COPD) undergoing mechanical ventilation.
    Penehyclidine
  • HY-142806
    RORγt inverse agonist 26 2738333-10-1 98%
    RORγt inverse agonist 26 is a potent reverse agonist of RORγt. RORγt inverse agonist 26 regulates the differentiation of Th17 cells and inhibits the production of IL-17. RORγt inverse agonist 26 has the potential for the research of inflammation and autoimmune diseases (extracted from patent WO2021228215A1, compound 1) .
    RORγt inverse agonist 26
  • HY-143728
    RIPK1-IN-10 2682889-51-4 98.25%
    RIPK1-IN-10 is a potent RIPK1 inhibitor, example 37, extracted from patent WO2021160109.
    RIPK1-IN-10
  • HY-145025
    ERK1/2 inhibitor 3 2737294-99-2 98%
    ERK1/2 inhibitor 3 is a potent inhibitor of ERK1/2. Mitogen-activated protein kinase (MAPK) plays an extremely important role in the signal transduction pathway, and extracellular signal regulated kinase (ERK) is a member of the MAPK family. ERK1/2 inhibitor 3 has the potential for the research or prevention of cancer, inflammation or other proliferative diseases (extracted from patent WO2021218912A1, compound 1).
    ERK1/2 inhibitor 3
  • HY-145373
    BMS-986143 1643372-83-1 98%
    BMS-986143 is an orally active, reversible BTK inhibitor with an IC50 of 0.26 nM. BMS-986143 also inhibits TEC, BLK, BMX, TXK FGR, YES1, ITK with IC50s of 3 nM, 5 nM, 7 nM, 10 nM, 15 nM,19 nM, 21 nM, respectively. BMS-986143 can be used for the research of autoimmune diseases.
    BMS-986143
  • HY-14654A
    Aspirin lithium 552-98-7 98%
    Aspirin (Acetylsalicylic Acid) lithium is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC50 values of 5 and 210 μg/mL, respectively. Aspirin lithium induces apoptosis. Aspirin lithium inhibits the activation of NF-κB. Aspirin lithium also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis.
    Aspirin lithium
  • HY-147215
    UC-1V150 927822-45-5 98%
    UC-1V150 is a specific TLR7 (Toll-like receptor) agonist that stimulates cellular immune responses and has anti-tumor activity. UC-1V150 can be used to synthesize ISAC (Immune-Stimulating Antibody Conjugates) molecule.
    UC-1V150
  • HY-147236
    TLR7/8 agonist 7 2567953-47-1 98%
    TLR7/8 agonist 7 (compound 10) is a TLR7/8 agonist. TLR7/8 agonist 7 activates a variety of immune cells and it can be used to synthesize immune stimulating antibody conjugate (ISAC) molecules. TLR7/8 agonist 7 can be used for the research of immunity.
    TLR7/8 agonist 7
  • HY-148115
    S1p receptor agonist 2 1354908-17-0 98%
    S1p receptor agonist 2 (compound 1) is an agonist of S1P5 receptor, exhibits selectivity over the S1P1 and/or S1P3 receptors. S1p receptor agonist 2 can be used for endogenous SIP signaling system research, and alleviating or preventing CNS disorders research, such as neurodegenerative disorders.
    S1p receptor agonist 2
  • HY-148805
    Vonifimod 2118903-18-5 98%
    Vonifimod is an immunomodulator.
    Vonifimod
  • HY-148980
    Polyinosinic acid 30918-54-8 98%
    Polyinosinic acid is a single stranded homonucleic acid, which is a Toll-like Receptor 3 (TLR3) ligand. Polyinosinic acid enhances cellular immune response through TLR3 and TRIF. Polyinosinic acid has potential applications in immune regulation.
    Polyinosinic acid
  • HY-14908A
    Vidofludimus hemicalcium 1354012-90-0 98%
    Vidofludimus (4sc-101; SC12267) hemicalcium is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus hemicalcium, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus hemicalcium also can be used for the research of fatty liver by targeting FXR.
    Vidofludimus hemicalcium
  • HY-150965
    NDT-30805 98%
    NDT-30805 is a selective NLRP3 inflammasome inhibitor. NDT-30805 is a triazolopyrimidinone derivative and inhibits IL-1β release in PBMCs with an IC50 of 0.013 μM. NDT-30805 can be used for the research of inflammation and innate immunity.
    NDT-30805
  • HY-151198
    CHF-6366 1615208-41-7 98%
    CHF-6366 is a potent M3 muscarinic antagonist and β2-adrenergic receptors agonist with pKi values of 10.4 and 11.4, respectively. CHF-6366 is also a weak calcium channel inhibitor (IC50~50 μM). CHF-6366 inhibits bronchoconstriction in guinea pigs. CHF-6366 can be used to research chronic obstructive pulmonary disease (COPD).
    CHF-6366
  • HY-155100
    BI 7446 2767011-00-5 98%
    BI 7446 is a cyclic dinucleotide (CDN)-based potent and selective stimulator of interferon genes (STING) agonist. BI 7446 can activate all five STING variants in cells and induce tumor-specific immune-mediated tumor rejection. BI 7446 can be used for immuno-oncology research.
    BI 7446
  • HY-15651A
    Alvelestat tosylate 1240425-05-1 98%
    Alvelestat (tosylate) is an orally bioavailable, affinity and selective inhibitor of neutrophil elastase (NE) with a pIC50 value of 7.9 nM, a Ki value of 9.4 nM and a Kd value of 9.5 nM.
    Alvelestat tosylate
  • HY-162878
    CHF-6523 2500579-21-3 98%
    CHF-6523 is an orally active PI3Kδ inhibitor that can be used in research related to chronic obstructive pulmonary disease (COPD).
    CHF-6523
  • HY-165504
    Nagstatin 126844-81-3
    Nagstatin is a naturally derived competitive inhibitor of N-acetyl-β-D-glucosaminidase (NAG-ase), with an IC50 of 0.0012 μg/mL and a Ki of 1.7×10-8 M against porcine-derived enzyme. Nagstatin enhances cellular immune responses in normal mice and reactivates suppressed cellular immune responses in tumor-bearing mice. Nagstatin can be used in the research of various diseases such as diabetes and leukemia.
    Nagstatin
Cat. No. Product Name / Synonyms Application Reactivity